Author(s): Carvalho,Diana ; Russo,Pedro ; Bernardes,Carlos ; Saiote,Joana ; Ramos,Gonçalo ; Mascarenhas,Luis ; Borges,Nuno ; Ramos,Jaime
Date: 2017
Origin: SciELO Portugal
Subject(s): Crohns disease; Hodgkins disease; chemically induced; Infliximab; Lymphoproliferative disorders; Tumor necrosis factor-α
Introduction: Lymphoproliferative disorders, particularly non-Hodgkins and Hodgkins lymphomas, are rare in patients with inflammatory bowel diseases. The use of thiopurines and infection by Epstein-Barr virus are well-known cofactors that can raise its prevalence. Other risk factors such as disease activity and biological treatment are the subject of discussion, without enough data in the literature to confirm a potential association. Methods: We report a case of Hodgkins lymphoma in a patient who had been treated with azathioprine and was on long-term monotherapy with infliximab. Conclusions: We stress the importance of recognizing the possible occurrence of a lymphoproliferative disorder in association with anti-tumor necrosis factor-α therapy.
